Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.61
EGLT's Cash to Debt is ranked lower than
69% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. EGLT: 2.61 )
Ranked among companies with meaningful Cash to Debt only.
EGLT' s Cash to Debt Range Over the Past 10 Years
Min: 0.18  Med: 2.61 Max: No Debt
Current: 2.61
Equity to Asset 0.52
EGLT's Equity to Asset is ranked lower than
70% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. EGLT: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
EGLT' s Equity to Asset Range Over the Past 10 Years
Min: -3.39  Med: -0.75 Max: 0.73
Current: 0.52
-3.39
0.73
F-Score: 3
Z-Score: 0.04
M-Score: 6.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -228.42
EGLT's Operating margin (%) is ranked lower than
62% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. EGLT: -228.42 )
Ranked among companies with meaningful Operating margin (%) only.
EGLT' s Operating margin (%) Range Over the Past 10 Years
Min: -1934.17  Med: -692.37 Max: -228.72
Current: -228.42
-1934.17
-228.72
Net-margin (%) -253.39
EGLT's Net-margin (%) is ranked lower than
64% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. EGLT: -253.39 )
Ranked among companies with meaningful Net-margin (%) only.
EGLT' s Net-margin (%) Range Over the Past 10 Years
Min: -2250.73  Med: -740.47 Max: -253.76
Current: -253.39
-2250.73
-253.76
ROE (%) -99.75
EGLT's ROE (%) is ranked lower than
81% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. EGLT: -99.75 )
Ranked among companies with meaningful ROE (%) only.
EGLT' s ROE (%) Range Over the Past 10 Years
Min: -444.79  Med: -265.80 Max: -86.8
Current: -99.75
-444.79
-86.8
ROA (%) -44.92
EGLT's ROA (%) is ranked lower than
66% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. EGLT: -44.92 )
Ranked among companies with meaningful ROA (%) only.
EGLT' s ROA (%) Range Over the Past 10 Years
Min: -155.7  Med: -123.58 Max: -49.73
Current: -44.92
-155.7
-49.73
ROC (Joel Greenblatt) (%) -1044.78
EGLT's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. EGLT: -1044.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EGLT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1093.04  Med: -771.13 Max: -672.52
Current: -1044.78
-1093.04
-672.52
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

EGLT Guru Trades in

Q2 2015

EGLT Guru Trades in Q2 2015

Jim Simons 36,400 sh (New)
» More
Q3 2015

EGLT Guru Trades in Q3 2015

Jim Simons 31,800 sh (-12.64%)
» More
Q4 2015

EGLT Guru Trades in Q4 2015

Jim Simons 47,300 sh (+48.74%)
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.96
EGLT's P/B is ranked higher than
74% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. EGLT: 1.96 )
Ranked among companies with meaningful P/B only.
EGLT' s P/B Range Over the Past 10 Years
Min: 1.41  Med: 3.07 Max: 9.79
Current: 1.96
1.41
9.79
P/S 6.00
EGLT's P/S is ranked higher than
68% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. EGLT: 6.00 )
Ranked among companies with meaningful P/S only.
EGLT' s P/S Range Over the Past 10 Years
Min: 5.15  Med: 66.41 Max: 670
Current: 6
5.15
670
Current Ratio 5.24
EGLT's Current Ratio is ranked higher than
55% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. EGLT: 5.24 )
Ranked among companies with meaningful Current Ratio only.
EGLT' s Current Ratio Range Over the Past 10 Years
Min: 0.17  Med: 2.29 Max: 7.42
Current: 5.24
0.17
7.42
Quick Ratio 5.18
EGLT's Quick Ratio is ranked higher than
56% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. EGLT: 5.18 )
Ranked among companies with meaningful Quick Ratio only.
EGLT' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 2.29 Max: 7.42
Current: 5.18
0.17
7.42
Days Inventory 265.51
EGLT's Days Inventory is ranked lower than
83% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 120.79 vs. EGLT: 265.51 )
Ranked among companies with meaningful Days Inventory only.
EGLT' s Days Inventory Range Over the Past 10 Years
Min: 102.49  Med: 102.49 Max: 102.49
Current: 265.51
Days Sales Outstanding 4.71
EGLT's Days Sales Outstanding is ranked higher than
94% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. EGLT: 4.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
EGLT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.72  Med: 81.92 Max: 321.28
Current: 4.71
4.72
321.28
Days Payable 827.64
EGLT's Days Payable is ranked higher than
98% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 63.23 vs. EGLT: 827.64 )
Ranked among companies with meaningful Days Payable only.
EGLT' s Days Payable Range Over the Past 10 Years
Min: 827.64  Med: 827.64 Max: 827.64
Current: 827.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.82
EGLT's Price/Net Cash is ranked higher than
76% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 5.74 vs. EGLT: 2.82 )
Ranked among companies with meaningful Price/Net Cash only.
EGLT' s Price/Net Cash Range Over the Past 10 Years
Min: 2.7  Med: 3.57 Max: 4.43
Current: 2.82
2.7
4.43
Price/Net Current Asset Value 2.63
EGLT's Price/Net Current Asset Value is ranked higher than
79% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. EGLT: 2.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EGLT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.53  Med: 3.33 Max: 4.13
Current: 2.63
2.53
4.13
Price/Tangible Book 2.24
EGLT's Price/Tangible Book is ranked higher than
75% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. EGLT: 2.24 )
Ranked among companies with meaningful Price/Tangible Book only.
EGLT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.23  Med: 2.87 Max: 3.51
Current: 2.24
2.23
3.51
Price/Median PS Value 0.09
EGLT's Price/Median PS Value is ranked higher than
97% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. EGLT: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
EGLT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 0.38 Max: 0.62
Current: 0.09
0.14
0.62
Earnings Yield (Greenblatt) (%) -60.67
EGLT's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. EGLT: -60.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EGLT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -127.28  Med: 0.00 Max: 0
Current: -60.67
-127.28
0

More Statistics

Revenue(Mil) $23
EPS $ -3.14
Short Percentage of Float8.65%
52-Week Range $5.60 - 16.59
Shares Outstanding(Mil)25.09

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 150 272
EPS($) -2.80 0.12 2.53
EPS without NRI($) -2.80 0.12 2.53
» More Articles for NAS:EGLT

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 

More From Other Websites
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on May... Apr 27 2016
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on May... Apr 27 2016
Egalet Announces Upcoming Opportunities for Community to Dispose of Prescription Medications Apr 21 2016
Egalet Announces Upcoming Opportunities for Community to Dispose of Prescription Medications Apr 21 2016
EGALET CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Apr 05 2016
Egalet Announces ALERRT(SM) Study Demonstrated Egalet-002 Required Significantly More Effort to... Mar 24 2016
Egalet Announces ALERRT(SM) Study Demonstrated Egalet-002 Required Significantly More Effort to... Mar 24 2016
EGALET CORP Financials Mar 17 2016
Huge Opportunity, and Risks, in 5 Top Abuse-Deterrent ER Opioids Mar 15 2016
EGALET CORP Files SEC form 10-K, Annual Report Mar 11 2016
Q4 2015 Egalet Corp Earnings Release - Before Market Open Mar 08 2016
EGALET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 08 2016
Egalet reports 4Q loss Mar 08 2016
Egalet reports 4Q loss Mar 08 2016
Egalet Reports Fourth Quarter and Full Year 2015 Financial Results Mar 08 2016
Capella Bioscience Completes Series A Financing of £11 million ($15.5 million) to Progress Antibody... Mar 08 2016
Egalet Announces FDA Acceptance of New Drug Application for ARYMO™ ER (Morphine Sulfate)... Feb 29 2016
Egalet to Host Conference Call and Webcast to Discuss Fourth Quarter 2016 Financial Results on March... Feb 23 2016
Egalet to Present at BIO CEO & Investor Conference Feb 09 2016
Egalet Signs Agreement with Septodont, Inc. to Promote SPRIX® (ketorolac tromethamine) Nasal Spray... Feb 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK